Literature DB >> 1528453

Embolization of intracranial arteriovenous malformations and fistulas with polyvinyl alcohol particles and platinum fibre coils.

P H Nakstad1, S J Bakke, J K Hald.   

Abstract

In order to reduce the recanalization rate of arteriovenous malformations and multiple dural arteriovenous fistulas, embolization was carried out with polyvinyl alcohol (PVA) particles combined with platinum fibre coils in 20 patients. The malformation was occluded more effectively than by PVA alone. Distal deposition of the emboli was obtained by improved steerable catheters (Tracker-18-unibody) and guidewires. The complication rate was lower than usually reported from studies using glue as embolic agent. It was concluded that the combination of PVA and fibre coils enhances the safety and effectiveness of embolization therapy and reduces the frequency of recanalization of intracranial AVMs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1528453     DOI: 10.1007/bf00588202

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  20 in total

1.  Revascularization of brain arteriovenous malformations after embolization with bucrylate.

Authors:  D Fournier; K Terbrugge; G Rodesch; P Lasjaunias
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

2.  Angiographic follow-up of large cerebral AVMs incompletely embolized with isobutyl-2-cyanoacrylate.

Authors:  F Viñuela; A J Fox; D Pelz; G Debrun
Journal:  AJNR Am J Neuroradiol       Date:  1986 Sep-Oct       Impact factor: 3.825

3.  Preoperative embolization of cerebral arteriovenous malformations with polyvinyl alcohol particles: experience in 51 adults.

Authors:  P D Purdy; D Samson; H H Batjer; R C Risser
Journal:  AJNR Am J Neuroradiol       Date:  1990-05       Impact factor: 3.825

4.  Carcinogenic potential of isobutyl-2-cyanoacrylate.

Authors:  D Samson; D Marshall
Journal:  J Neurosurg       Date:  1986-10       Impact factor: 5.115

5.  Clinical versus experimental use of isobutyl-2-cyanoacrylate.

Authors:  A Berenstein; G Hieshima
Journal:  J Neurosurg       Date:  1987-08       Impact factor: 5.115

6.  Arteriovenous malformations of the brain: recent results of endovascular therapy.

Authors:  A J Fox; D M Pelz; D H Lee
Journal:  Radiology       Date:  1990-10       Impact factor: 11.105

7.  Endovascular treatment of intracerebral arteriovenous angiomas. Technique, indications and results.

Authors:  L Picard; J Moret; J Lepoire; L Castaing; J F Hirsch; F Mikol; J Montaut; Z Per; J Roland; M Sachs
Journal:  J Neuroradiol       Date:  1984       Impact factor: 3.447

8.  Treatment of arteriovenous malformations of the brain with combined embolization and stereotactic radiosurgery: results after 1 and 2 years.

Authors:  R C Dawson; R W Tarr; S T Hecht; C A Jungreis; L D Lunsford; R Coffey; J A Horton
Journal:  AJNR Am J Neuroradiol       Date:  1990 Sep-Oct       Impact factor: 3.825

9.  Staged treatment of arteriovenous malformations of the brain.

Authors:  B T Andrews; C B Wilson
Journal:  Neurosurgery       Date:  1987-09       Impact factor: 4.654

10.  Combined neuroradiological and neurosurgical treatment of intracerebral arteriovenous malformations.

Authors:  D Adelt; H Brückmann; W Krenkel; W Hacke; H Zeumer
Journal:  J Neurol       Date:  1988-07       Impact factor: 4.849

View more
  3 in total

1.  Endovascular Treatment of Cerebral AVM with Onyx - Initial Experience.

Authors:  S Joseph; H C Chadaga; K Murali
Journal:  Interv Neuroradiol       Date:  2005-10-27       Impact factor: 1.610

2.  Treatment of pseudoaneurysm of internal maxillary artery: a case report.

Authors:  Jimmy Charles Melo Barbalho; Eliardo Silveira Santos; José Maria Sampaio Menezes; Fabricio Rocha Gonçalves; Otacilio Luiz Chagas
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2010-06

3.  Superselective angiography, embolisation and surgery in treatment of arteriovenous malformations of the brain.

Authors:  P H Nakstad; H Nornes
Journal:  Neuroradiology       Date:  1994-07       Impact factor: 2.804

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.